<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncopathology</journal-id><journal-title-group><journal-title xml:lang="en">Oncopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкопатология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2618-7019</issn><issn publication-format="electronic">3034-3534</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">708416</article-id><article-id pub-id-type="doi">10.17650/2619-7019-2018-1-1-12-17</article-id><article-id pub-id-type="edn">NDCTOI</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Leading article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Oncopathology - dawn of a new era</article-title><trans-title-group xml:lang="ru"><trans-title>Онкопатология: начало новой эры</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Badve</surname><given-names>S. S.</given-names></name><name xml:lang="ru"><surname>Бадве</surname><given-names>С. С.</given-names></name></name-alternatives><email>abv@abvpress.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gokmen-Polar</surname><given-names>Y.</given-names></name><name xml:lang="ru"><surname>Гокмен-Полар</surname><given-names>Ю.</given-names></name></name-alternatives><email>abv@abvpress.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Indiana University</institution></aff><aff><institution xml:lang="ru">Университет штата Индиана</institution></aff></aff-alternatives><aff id="aff2"><institution></institution></aff><pub-date date-type="pub" iso-8601-date="2018-02-18" publication-format="electronic"><day>18</day><month>02</month><year>2018</year></pub-date><volume>1</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>12</fpage><lpage>17</lpage><history><date date-type="received" iso-8601-date="2026-06-09"><day>09</day><month>06</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, АБВ-пресс</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://oncopathology.abvpress.ru/2618-7019/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://oncopathology.abvpress.ru/2618-7019/article/view/708416">https://oncopathology.abvpress.ru/2618-7019/article/view/708416</self-uri><abstract xml:lang="en"><p>Pathology by definition is the study of disease originating from the Greek “pathos” - “suffering” and “ology” - “study of”. In medicine, it is the branch of medical science that studies the causes and effects of diseases. Advances in the field of pathology first led to the establishment of anatomic pathology as a separate discipline. Further advances have made it necessary for pathologists to sub-specialize in the field of oncology. Tumor pathology is no longer the discipline that recognizes the presence of a tumor and determines the morphological/patho-logical characteristics of the tumor. Advances in genomic technologies have resulted in better understanding of the biology of tumors forming the basis of “oncopathology” (“onco” originating from the Greek “onkos” - tumor). Oncopathology combines precision oncology with the predictive pathology tailored for each individual, as it is key to translate the prognostic biomarkers into predictive biomarkers to improve the efficacy of clinical therapeutics in the management of cancer. This article highlights the recent developments and underlines the needfor the discipline of oncopathology (and a journal devoted to it).</p></abstract><trans-abstract xml:lang="ru"><p>Онкопатология: начало новой эры S.S. Badve1, 2, Y. Gökmen-Polar3 1 Кафедра патологии и медицины, медицинский факультет Университета Индианы; 350 W. 10th Street, Индианаполис 46202, США; 2 Онкологический центр Melvin &amp; Bren Simon Университета Индианы; 3 635 Barnhill Drive, Индианаполис 46202, США Термин «патология» происходит от греческого «pathos» (страдание) и «logos» (изучение). Патология - отрасль медицинской науки, изучающая причины и последствия различных заболеваний. Достижения в области патологии привели к становлению патологической анатомии как отдельной дисциплины. Дальнейший прогресс этой отрасли науки обусловил необходимость дополнительной специализации патологоанатомов в области онкологии. Онкологическая патология больше не является дисциплиной, которая занимается лишь выявлением опухолей и определением их морфологических/патологических характеристик. Успехи геномных технологий привели к лучшему пониманию биологии опухолей, лежащей в основе онкопатологии (от греч. «onkos» - опухоль). Онкопатология сочетает в себе прецизионную онкологию и прогностическую патологию, адаптированную для каждого пациента, так как это является ключевым фактором для преобразования прогностических биомаркеров в предиктивные с целью повышения эффективности противоопухолевой терапии. В настоящей статье рассмотрены последние разработки в этой области, показана важность онкопатологии и посвященного ей журнала.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cancer</kwd><kwd>predictive markers</kwd><kwd>prognosis</kwd><kwd>pathology</kwd><kwd>Gene-panel</kwd><kwd>mutational panel</kwd><kwd>next-generation sequencing</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак</kwd><kwd>предиктивные маркеры</kwd><kwd>прогноз</kwd><kwd>патология</kwd><kwd>генная панель</kwd><kwd>мутационная панель</kwd><kwd>секвенирование нового поколения</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Amin M.B., Greene F.L., Edge S.B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9. PMID: 28094848. DOI: 10.3322/ caac.21388.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Brem S., Cotran R., Folkman J. Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 1972;48(2):347-56. PMID: 4347034.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Folkerth R.D. Histologic measures of angiogenesis in human primary brain tumors. Cancer Treat Res 2004;117:79-95. PMID: 15015553.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jain R., Griffith B., Alotaibi F. et al. Glioma angiogenesis and perfusion imaging: understanding the relationship between tumor blood volume and leakiness with increasing glioma grade. AJNR Am J Neuroradiol 2015;36(11):2030-5. PMID: 26206809. DOI: 10.3174/ajnr. A4405.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Adams S., Gray R.J., Demaria S. et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32(27):2959-66. PMID: 25071121. DOI: 10.1200/JCO.2013.55.0491.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hendry S., Salgado R., Gevaert T. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 2017;24(6):311-35. PMID: 28777143. DOI: 10.1097/ PAP.0000000000000161.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Galon J., Mlecnik B., Bindea G. et al. Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol 2014;232(2):199-209. PMID: 24122236. DOI: 10.1002/ path.4287.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Wolff A.C., Hammond M.E., Hicks D.G. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31(31):3997-4013. PMID: 24101045. DOI: 10.1200/ JCO.2013.50.9984.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bang Y.J., Van Cutsem E., Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376(9742):687-97.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Van Cutsem E., Bang Y.J., Feng-Yi F. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 2015;18(3):476-84. PMID: 25038874. DOI: 10.1007/s10120-014-0402-y.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lin G., Fan X., Zhu W. et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. On-cotarget 2017;8(48):83986-94. PMID: 29137398. DOI: 10.18632/onco-target.20233.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kulangara K., Hanks D.A., Waldroup S. et al. Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immu-nohistochemistry assay PD-L1 IHC 22C3 pharmDx. American Society of Clinical Oncology Annual Meeting 2017, Chicago, IL.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Raymond V.M., Gray S.W., Roychowd-hury S. et al. Germline findings in tumor-only sequencing: points to consider for clinicians and laboratories. J Natl Cancer Inst 2015;108(4). pii: djv351. PMID: 26590952. DOI: 10.1093/jnci/djv351.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kamps R., Brandao R.D., Bosch B.J. et al. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification.Int J Mol Sci 2017;18(2):E308. PMID: 28146134. DOI: 10.3390/ijms18020308.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther 2017;102(6):934-41. PMID: 28795401. DOI: 10.1002/cpt.814.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sosman J.A., Kim K.B., Schuchter L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8): 707-14. PMID: 22356324. DOI: 10.1056/NEJMoa1112302.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hyman D.M., Puzanov I., Subbiah V. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373(8):726-36. PMID: 26287849. DOI: 10.1056/NEJ-Moa1502309.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Louis D.N., Perry A., Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131(6):803-20. PMID: 27157931. DOI: 10.1007/s00401-016-1545-1.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med 2013;5(209):209ra153. PMID: 24174329. DOI: 10.1126/scitranslmed.3006802.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Rotow J., Bivona T.G. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17(11):637-58. PMID: 29068003. DOI: 10.1038/nrc.2017.84.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Odogwu L., Mathieu L., Goldberg K.B. et al. FDA benefit-risk assessment of osimertinib for the treatment of metastatic non-small cell lung cancer harboring epidermal growth factor receptor T790M mutation. Oncologist 2017: theoncologist.2017-0425. PMID: 29242281. DOI: 10.1634/theoncologist.2017-0425.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Mayo-de-Las-Casas C., Garzon Ibanez M., Jordana-Ariza N. et al. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Rev Mol Diagn 2018;18(1): 35-45. PMID: 29172773. DOI: 10.1080/14737159.2018.1407243.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Chaudhuri A.A., Chabon J.J., Lovejoy A.F. et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov 2017;7(12):1394-403. PMID: 28899864. DOI: 10.1158/2159-8290.CD-17-0716.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sparano J.A., O'Neill A., Alpaugh K. et al. Circulating tumor cells (CTCs) 5 years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. San Antonio Breast Cancer Symposium 2017.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Alix-Panabieres C., Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6(5):479-91. PMID: 26969689. DOI: 10.1158/2159-8290.CD-15-1483.</mixed-citation></ref></ref-list></back></article>
